SNN Sales Beat but Earnings Miss on Weak Results - Analyst Blog
May 06 2013 - 3:28AM
Zacks
Smith & Nephew plc (SNN) reported adjusted
earnings per share (EPS) of 18.5 cents or EPADS of 93 cents in the
first quarter of 2013, missing the year-ago EPADS of 97 cents.
Further, the adjusted results trailed the Zacks Consensus Estimate
(EPADS) of 95 cents.
On a reported basis, EPS of 15.7 cents or EPADS of 79 cents in the
first quarter missed the year-ago EPS of 17.7 cents or EPADS of 89
cents.
Revenues
Revenues were $1,075 million in the quarter, up 1% (underlying,
after considering currency translation, inclusion of Healthpoint
growth and exclusion of Bioventus transaction) year over year.
Moreover, the top line beat the Zacks Consensus Estimate of $1,064
million. Excluding the impact of the Healthpoint acquisition,
revenue decreased 1% on an underlying basis. Two lesser sales-days
in the last quarter led to revenue decline of approximately 3%.
On a regional basis, during the reported quarter, revenues from the
U.S. and Emerging and International Markets recorded underlying
growth of 4% ($460 million) and 19% ($130 million), respectively.
The Healthpoint acquisition led the growth in the U.S. market.
Growth in Emerging and International Markets was led by robust
sales in the Chinese and Middle-Eastern market. The macroeconomic
environment in Europe dragged the company’s performance in
Established Markets by 5% on an underlying basis ($485
million).
Segments
Smith & Nephew’s business framework comprises two divisions –
Advanced Surgical Devices (“ASD”) and Advanced Wound Management
(“AWM”).
ASD recorded revenues of $760 million in the quarter, down 2% on an
underlying basis, primarily due to fewer selling days. Within this
business, Smith & Nephew experienced 2% decline in the U.S.
Segment revenues in other Established markets decreased 7% on a
year-over-year basis as the situation in Europe continues to remain
an overhang. Maintaining the momentum, the company recorded 16%
growth in the Emerging and International markets. Also, pricing
pressure for the ASD segment remained unchanged in the quarter.
While the knee implant business reported 6% decline in revenues
globally, against the market growth rate of (1%), revenues from the
hip implant franchise decreased 6% (down 3% excluding the
Birmingham Hip Resurfacing system) against market growth rate of
(1%). This was mainly due to a strong comparable year-ago
quarter.
Smith & Nephew continues to battle headwinds such as timing of
the product cycle against other players, sluggish European market
and softness in the company’s largest market in Europe — Germany,
besides ongoing softness for metal-on-metal franchise for its
orthopaedic reconstruction business.
Smith & Nephew recorded 4% growth in its sports medicine joint
repair franchise, while arthroscopic enabling technologies
witnessed 7% downfall on a year-over-year basis. The decline was
mainly on account of pressure on hospital budgets in end-markets.
The trauma business maintained its positive momentum and recorded
8% growth, ahead of the market growth rate of 4%.
AWM recorded strong growth of 12% (underlying) year over year to
$315 million in the quarter against 2% market growth rate.
Excluding the impact of the Healthpoint acquisition, AWM revenues
inched up 5%. Revenues in the U.S. surged 28% on a year-over-year
basis. The company witnessed 1% growth in the Established Markets
despite softness across Europe. The Emerging and International
Markets recorded a robust hike of 29%.
Under AWM, advanced wound care revenues increased 1% to $200
million on the back of exudate and infection management products.
Revenues of advanced wound devices improved 26% to $48 million as
Smith & Nephew continued to gain market share in NPWT and
sustained momentum in the Japanese market. Advanced wound
bioactives revenues were $67 million, up 49% from the prior-year
quarter.
Margins
Gross margin expanded 10 basis points (bps) year over year to 75%
in the quarter. The company witnessed a 3.4% rise in selling,
general and administrative expenses to $547 million and a 20.9%
rise in research and development expenses to $52 million. As a
result, operating margin contracted 260 bps to 19.3% in the
quarter. Overall, trading profit margin (operating margin after
taking into account one-time transactions) decreased 90 bps to
22.4% in the quarter.
Among the segments, ASD trading profit margin improved 20 bps to
24.3% on the back of restructuring efforts. However, the trading
profit margin at the AWM division recorded a contraction of 290 bps
due to the Healthpoint acquisition.
Acquisition of Indian Company
In a separate story, Smith & Nephew announced an agreement to
takeover Adler Mediequip Private Limited and with it, the brands
and assets of Sushrut Surgicals Private Limited, a leader in
mid-tier, orthopaedic trauma products for the Indian market.
While we await further details on the agreement, the buyout gives
Smith & Nephew an opportunity to gain a foothold in the
burgeoning trauma market in India. The acquisition will also
support the company’s plans to develop offerings for the mid-tier
market in India.
Our Take
Smith & Nephew reported a mixed quarter to begin 2013. As
expected, the company witnessed slowdown in revenue growth due to
sustained weakness in the orthopaedic reconstruction. The softness
in the European market, especially Germany was another headwind in
the quarter.
Nonetheless, we are encouraged to note the gradual stability in the
U.S. market, though the challenging scenario in Europe continues to
be an overhang. Notably, the company’s increasing focus on AWM
franchise is paying off. We are also encouraged by the company’s
focus on the lucrative emerging markets such as China and Middle
East.
Accordingly, the stock carries a Zacks Rank #3 (Hold). While we
prefer to remain on the sidelines for Smith & Nephew, other
medical stocks such as Conceptus Inc. (CPTS) and
LeMaitre Vascular Inc. (LMAT), carrying a Zacks
Rank #1 (Strong Buy) warrant a look. Hanger Inc.
(HGR), carrying a Zacks Rank #2 (Buy) is also expected to do
well.
CONCEPTUS INC (CPTS): Free Stock Analysis Report
HANGER ORTHOPED (HGR): Free Stock Analysis Report
LEMAITRE VASCLR (LMAT): Free Stock Analysis Report
SMITH & NEPHEW (SNN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jul 2023 to Jul 2024